Literature DB >> 8839617

The immunopathogenic role of complement in human muscle disease.

J R Mendell1, T S Garcha, J T Kissel.   

Abstract

The complement system has been shown to play a pathogenic role in only a small number of muscle diseases. A complement-induced microangiopathy is important in dermatomyositis and in the rare disorder, necrotizing myopathy with pipestem capillaries. Recent studies demonstrate the reversibility of microvascular damage in dermatomyositis by intravenous immune globulin which appears to intercept the assembly and deposition of membrane attach complex. In myasthenia gravis, complement-mediated lysis directed at the acetylcholine receptor leads to a cascade of events reducing the number of receptors, simplifying the complex architecture of the junctional folds and decreasing the available surface for the insertion of new receptors. The newest condition in which a role for complement has been demonstrated is X-linked vacuolated myopathy. The condition is of interest because membrane attack complex deposits result in shedding of complement-laden membrane fragments in contrast to a cytolytic process as the consequence of assembly of the terminal complement components.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8839617     DOI: 10.1097/00019052-199606000-00014

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  3 in total

1.  A Rare Case of Mixed Connective Tissue Disease (MCTD) with Intricate Features of Lupus, Polymyositis and Rheumatoid Arthritis Presenting with Severe Myositis.

Authors:  Lokesh S; Kadavanu Tony; Suresh V; Balakrishna Malepati
Journal:  J Clin Diagn Res       Date:  2015-03-01

Review 2.  Complement and systemic lupus erythematosus.

Authors:  Mark J Walport
Journal:  Arthritis Res       Date:  2002-05-09

3.  Hypocomplementemia as a Risk Factor for Organ Damage Accrual in Patients with Systemic Lupus Erythematosus.

Authors:  Warren Raymond; Gro Eilertsen; Johannes Nossent
Journal:  J Immunol Res       Date:  2018-12-30       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.